Lake Forest, California-based InMode Ltd, a provider of medical technologies, has raised $70 million for its IPO after pricing its 5 million shares at $14 per share. The stock began trading August 8, 2019 on the NASDAQ under the ticker symbol “INMD.” Barclays Capital Inc. and UBS Investment Bank are the lead underwriters. InMode’s pre-IPO backers include Israel Healthcare Ventures.
LAKE FOREST, Calif., Aug. 7, 2019 /PRNewswire/ — InMode Ltd. (“InMode”), announced today the pricing of its initial public offering of 5,000,000 ordinary shares at an initial public offering price of $14.00 per ordinary share. The underwriters of the offering will also have a 30-day option to purchase up to an additional 750,000 ordinary shares from InMode at the initial public offering price. The estimated gross proceeds, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $70.0 million. The shares are expected to begin trading on August 8, 2019 on the Nasdaq Global Select Market under the symbol “INMD.” The closing of the offering is expected to occur on August 12, 2019, subject to the satisfaction of customary closing conditions.
Barclays Capital Inc. and UBS Investment Bank are acting as the representatives of the underwriters and joint book-running managers for the proposed offering. Canaccord Genuity LLC is acting as lead manager for the proposed offering. Robert W. Baird & Co. Incorporated is acting as co-manager for the proposed offering.
The Company’s registration statement related to the offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus. Copies of the prospectus related to the offering, when available, may also be obtained, Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at Barclaysprospectus@broadridge.com, or by telephone at (888) 603-5847; or UBS Investment Bank, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275, or by email at firstname.lastname@example.org. SEC filings are available to the public from the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
InMode Ltd. is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio-frequency (RF) technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.